Magnesium in PDB 6usx: Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer

The structure of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer, PDB code: 6usx was solved by G.P.Vigers, D.J.Smith, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å)	29.51 / 2.27
Space group	C 2 2 2
Cell size a, b, c (Å), α, β, γ (°)	88.570, 156.490, 62.980, 90.00, 90.00, 90.00
R / Rfree (%)	18.7 / 25

The binding sites of Magnesium atom in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer (pdb code 6usx). This binding sites where shown within 5.0 Angstroms radius around Magnesium atom.
In total 2 binding sites of Magnesium where determined in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer, PDB code: 6usx:
Jump to Magnesium binding site number: 1; 2;

Magnesium binding site 1 out of 2 in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer


Mono view


Stereo pair view

A full contact list of Magnesium with other atoms in the Mg binding site number 1 of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer within 5.0Å range: probe atom residue distance (Å) B Occ A:Mg202 b:43.4 occ:1.00 O A:HOH309 1.9 33.2 1.0 HG A:SER17 1.9 39.8 0.0 O A:HOH319 2.0 40.9 1.0 OG A:SER17 2.1 35.9 1.0 O2B A:GDP201 2.1 39.1 1.0 O A:HOH304 2.2 39.9 1.0 O A:HOH307 2.3 34.9 1.0 HB2 A:SER17 3.1 34.4 1.0 CB A:SER17 3.1 33.0 1.0 PB A:GDP201 3.3 36.4 1.0 H A:SER17 3.4 35.6 1.0 HA A:PRO34 3.4 41.6 1.0 HD2 A:TYR32 3.5 42.0 1.0 O3B A:GDP201 3.5 34.1 1.0 HB3 A:SER17 3.8 34.4 1.0 N A:SER17 4.0 35.1 1.0 OD2 A:ASP57 4.0 37.6 1.0 HB1 A:ALA59 4.0 41.2 1.0 HB3 A:TYR32 4.1 42.6 1.0 CA A:SER17 4.1 36.1 1.0 O2A A:GDP201 4.2 43.3 1.0 HB2 A:ALA59 4.2 41.2 1.0 O A:ASP33 4.2 35.1 1.0 HB2 A:LYS16 4.2 34.2 1.0 O3A A:GDP201 4.3 37.3 1.0 OD1 A:ASP57 4.3 41.4 1.0 CA A:PRO34 4.3 42.1 1.0 O1B A:GDP201 4.4 33.2 1.0 CD2 A:TYR32 4.4 38.5 1.0 HE2 A:LYS16 4.4 35.9 1.0 HA A:SER17 4.5 35.0 1.0 O A:TYR32 4.5 44.0 1.0 CG A:ASP57 4.6 39.9 1.0 CB A:ALA59 4.6 40.0 1.0 PA A:GDP201 4.6 39.1 1.0 O31 A:M1R203 4.6 37.3 1.0 O A:THR58 4.7 36.6 1.0 O1A A:GDP201 4.8 38.5 1.0 HB3 A:PRO34 4.8 43.0 1.0 O A:ILE36 4.8 48.4 1.0 C A:ASP33 4.9 37.3 1.0 HZ3 A:LYS16 4.9 37.8 1.0 HZ2 A:LYS16 4.9 37.8 1.0 O A:PRO34 4.9 40.1 1.0 O A:HOH327 5.0 35.0 1.0 CB A:TYR32 5.0 41.9 1.0 N A:PRO34 5.0 37.5 1.0

Magnesium binding site 2 out of 2 in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer


Mono view


Stereo pair view

A full contact list of Magnesium with other atoms in the Mg binding site number 2 of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer within 5.0Å range: probe atom residue distance (Å) B Occ B:Mg202 b:51.0 occ:1.00 HG B:SER17 1.8 43.5 0.0 O B:HOH306 2.0 42.1 1.0 OG B:SER17 2.1 38.9 1.0 O2B B:GDP201 2.1 45.6 1.0 O B:HOH303 2.4 33.8 1.0 HB2 B:SER17 3.2 39.7 1.0 CB B:SER17 3.2 38.9 1.0 HA B:PRO34 3.4 65.3 1.0 H B:SER17 3.5 40.9 1.0 HD2 B:TYR32 3.5 68.0 1.0 PB B:GDP201 3.5 39.9 1.0 HB2 B:ALA59 3.7 46.3 1.0 O1B B:GDP201 3.8 37.3 1.0 HB3 B:SER17 3.8 39.7 1.0 OD2 B:ASP57 3.8 43.8 1.0 HE2 B:LYS16 3.9 37.1 1.0 OD1 B:ASP57 4.0 47.6 1.0 N B:SER17 4.0 39.2 1.0 HB2 B:LYS16 4.0 36.7 1.0 HB1 B:ALA59 4.1 46.3 1.0 CA B:SER17 4.1 42.5 1.0 O B:ASP33 4.1 58.6 1.0 HB3 B:TYR32 4.3 62.9 1.0 CG B:ASP57 4.3 43.4 1.0 CB B:ALA59 4.3 45.3 1.0 HA B:SER17 4.3 40.6 1.0 O1A B:GDP201 4.4 48.4 1.0 CA B:PRO34 4.4 64.1 1.0 O B:ILE36 4.4 57.5 1.0 CD2 B:TYR32 4.4 65.9 1.0 O B:THR58 4.5 43.4 1.0 O3A B:GDP201 4.5 41.5 1.0 O B:PRO34 4.5 65.3 1.0 O3B B:GDP201 4.6 43.1 1.0 PA B:GDP201 4.7 39.5 1.0 C B:PRO34 4.8 66.5 1.0 O31 B:M1R203 4.8 42.8 1.0 O B:TYR32 4.8 63.6 1.0 CE B:LYS16 4.8 36.3 1.0 HE2 B:TYR32 4.9 72.6 1.0 C B:ASP33 5.0 65.6 1.0 CB B:LYS16 5.0 36.1 1.0 HZ2 B:LYS16 5.0 40.2 1.0 O2A B:GDP201 5.0 43.5 1.0 HB3 B:ALA59 5.0 46.3 1.0 HA B:ALA59 5.0 47.1 1.0

J.B.Fell, J.P.Fischer, B.R.Baer, J.F.Blake, K.Bouhana, D.M.Briere, K.D.Brown, L.E.Burgess, A.C.Burns, M.R.Burkard, H.Chiang, M.J.Chicarelli, A.W.Cook, J.J.Gaudino, J.Hallin, L.Hanson, D.P.Hartley, E.J.Hicken, G.P.Hingorani, R.J.Hinklin, M.J.Mejia, P.Olson, J.N.Otten, S.P.Rhodes, M.E.Rodriguez, P.Savechenkov, D.J.Smith, N.Sudhakar, F.X.Sullivan, T.P.Tang, G.P.Vigers, L.Wollenberg, J.G.Christensen, M.A.Marx. Identification of the Clinical Development CANDIDATEMRTX849, A Covalent KRASG12CINHIBITOR For the Treatment of Cancer. J.Med.Chem. 2020.
ISSN: ISSN 0022-2623
PubMed: 32250617
DOI: 10.1021/ACS.JMEDCHEM.9B02052